<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013763</url>
  </required_header>
  <id_info>
    <org_study_id>038/2562(EC1)</org_study_id>
    <nct_id>NCT04013763</nct_id>
  </id_info>
  <brief_title>Outcome of Specific IgE Level in Children With IgE-mediated Wheat Allergy After Stop Using Wheat Containing Skin Care</brief_title>
  <official_title>Outcome of Specific IgE Level in Children With IgE-mediated Wheat Allergy After Stop Using Wheat Containing Skin Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council of Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Wheat allergy is increasing in Thailand. Some studies show that cutaneous exposure of
      allergen may cause allergy and there are many wheat containing skin care products that are
      over-the-counter. So the purpose of our study is to determine level of specific
      immunoglobulin E antibodies to wheat and omega-5 gliadin in wheat allergy patients after stop
      using wheat containing skin care products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All children in this study were sensitized to wheat. Each patient was clinically evaluated,
      with focus on wheat allergy by medical history, medical examination included skin status
      (suspected atopic dermatitis or not). Blood sample was taken for baseline determination of
      immunoglobulin E antibodies to wheat and to omega-5 gliadin. Transepidermal water loss was
      examined in case with atopic dermatitis. The primary outcome was the specific immunoglobulin
      E antibodies to wheat and omega-5 gliadin in case that stop using wheat containing skin care
      product and case that continue using products.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific IgE to wheat and omega-5 gliadin level</measure>
    <time_frame>1 year</time_frame>
    <description>To follow-up the level of wheat and omega5 gliadin specificIgE after stop using the wheat containing skin care product compare to patients who continue using the product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of transepidermal water loss</measure>
    <time_frame>1 year</time_frame>
    <description>To follow up the transepidermal water loss in patients with atopic dermatitis, comparing the group that continue using the product to the group that stop using the product.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Wheat Allergy</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>Atopic dermatitis with stop using product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>case wheat allergy with atopic dermatitis and stop using wheat containing skin care products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis with containing using product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>case wheat allergy with atopic dermatitis and continue using wheat containing skin care products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non atopic dermatitis with stop using product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>case wheat allergy with normal skin and stop using wheat containing skin care products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non atopic dermatitis with continue using product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>case wheat allergy with normal skin and continue using wheat containing skin care products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis with no product use</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non atopic dermatitis with no product use</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>wheat containing skin care products</intervention_name>
    <description>stop or continue using wheat containing skin care products</description>
    <arm_group_label>Atopic dermatitis with containing using product</arm_group_label>
    <arm_group_label>Atopic dermatitis with stop using product</arm_group_label>
    <arm_group_label>Non atopic dermatitis with continue using product</arm_group_label>
    <arm_group_label>Non atopic dermatitis with stop using product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children age 1 to 18 years

          -  History of IgE-mediated wheat allergy

        Exclusion Criteria:

          -  Parents refused to sign the consent

          -  severe atopic dermatitis

          -  on oral immunothery

          -  severe IgE mediated reaction after using wheat containing skin care product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Punchama Pacharn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Punchama Pacharn, MD</last_name>
    <phone>024197000</phone>
    <phone_ext>5670</phone_ext>
    <email>punchama@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Siriraj hospital</name>
      <address>
        <city>Bangkok noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chanaporn Mokkhamakkul, MD</last_name>
      <phone>+66840711179</phone>
      <email>chanaporn.m@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Nakamura M, Yagami A, Hara K, Sano A, Kobayashi T, Aihara M, Hide M, Chinuki Y, Morita E, Teshima R, Matsunaga K. A new reliable method for detecting specific IgE antibodies in the patients with immediate type wheat allergy due to hydrolyzed wheat protein: correlation of its titer and clinical severity. Allergol Int. 2014 Jun;63(2):243-9. doi: 10.2332/allergolint.13-OA-0618. Epub 2014 Apr 25.</citation>
    <PMID>24759554</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wheat allergy</keyword>
  <keyword>skin sensitization</keyword>
  <keyword>specific IgE</keyword>
  <keyword>wheat containing skin care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Wheat Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

